12:00 AM
 | 
May 19, 2008
 |  BioCentury  |  Strategy

Delta means change

KAI Pharmaceuticals Inc. regained rights to cardiovascular compound KAI-9803 from former partner Daiichi Sankyo Co. Ltd. last year and last week found a new partner in Bristol-Myers Squibb Co. The deal provides KAI capital and a chance to develop commercial expertise to apply to its own pipeline, and gives Bristol-Myers a new target to add to its cardiovascular pipeline.

KAI-9803 is an isozyme-selective inhibitor of the protein kinase C delta pathway that is being developed to prevent ischemia/reperfusion injury in acute myocardial infarction (AMI). The compound acts upstream of both apoptotic and necrotic pathways by inhibiting PKC delta translocation into the mitochondria, preventing cell death that would otherwise occur in heart tissue during a heart attack (see BioCentury, March 21, 2005).

"Selective inhibition of the delta PKC isozyme by KAI-9803...

Read the full 664 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >